Which has preferable valuation and earnings, BRKR or TECH?

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bruker $3.44B 2.78 -$8.60M -$0.24 N/A Bio-Techne $1.22B 6.53 $73.40M $0.69 73.70

Is BRKR or TECH more profitable?

Bio-Techne has a net margin of 9.05% compared to Bruker's net margin of -0.65%. Bio-Techne's return on equity of 13.57% beat Bruker's return on equity. Company Net Margins Return on Equity Return on Assets Bruker -0.65% 11.60% 4.25% Bio-Techne 9.05% 13.57% 10.66%

Which has stronger earnings & valuation, DHR or TECH?

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Danaher $24.57B 5.14 $3.61B $5.17 34.51 Bio-Techne $1.22B 6.53 $73.40M $0.69 73.70

Is DHR or TECH more profitable?

Danaher has a net margin of 14.89% compared to Bio-Techne's net margin of 9.05%. Bio-Techne's return on equity of 13.57% beat Danaher's return on equity. Company Net Margins Return on Equity Return on Assets Danaher 14.89% 10.91% 6.94% Bio-Techne 9.05% 13.57% 10.66%

Bio-Techne (TECH) Competitors

$50.85 +1.08 (+2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$50.74 -0.11 (-0.22%)

As of 07:42 PM Eastern

Compare

TECH vs. BRKR, A, BIO, CRL, and DHR

Should you buy Bio-Techne stock or one of its competitors? MarketBeat compares Bio-Techne with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Techne include Bruker (BRKR), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), and Danaher (DHR).

How does Bio-Techne compare to Bruker?

Bruker (NASDAQ:BRKR) and Bio-Techne (NASDAQ:TECH) are both mid-cap life sciences tools & services companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Bio-Techne has a net margin of 9.05% compared to Bruker's net margin of -0.65%. Bio-Techne's return on equity of 13.57% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-0.65%	11.60%	4.25%
Bio-Techne	9.05%	13.57%	10.66%

Bruker has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.78	-$8.60M	-$0.24	N/A
Bio-Techne	$1.22B	6.53	$73.40M	$0.69	73.70

Bruker currently has a consensus target price of $50.54, suggesting a potential downside of 19.40%. Bio-Techne has a consensus target price of $65.92, suggesting a potential upside of 29.64%. Given Bio-Techne's stronger consensus rating and higher probable upside, analysts clearly believe Bio-Techne is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.40
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

79.5% of Bruker shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 27.2% of Bruker shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Bruker had 7 more articles in the media than Bio-Techne. MarketBeat recorded 8 mentions for Bruker and 1 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.89 beat Bruker's score of 0.54 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Overall Sentiment
Bruker	Positive
Bio-Techne	Very Positive

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.6%. Bruker pays out -83.3% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Bio-Techne beats Bruker on 14 of the 18 factors compared between the two stocks.

How does Bio-Techne compare to Agilent Technologies?

Bio-Techne (NASDAQ:TECH) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Bio-Techne has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Agilent Technologies has a net margin of 19.55% compared to Bio-Techne's net margin of 9.05%. Agilent Technologies' return on equity of 24.33% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Agilent Technologies	19.55%	24.33%	12.99%

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.6%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.7%. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bio-Techne currently has a consensus price target of $65.92, indicating a potential upside of 29.64%. Agilent Technologies has a consensus price target of $161.71, indicating a potential upside of 17.18%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Agilent Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.94

99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Agilent Technologies had 40 more articles in the media than Bio-Techne. MarketBeat recorded 41 mentions for Agilent Technologies and 1 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.89 beat Agilent Technologies' score of 0.77 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Techne	Very Positive
Agilent Technologies	Positive

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	6.53	$73.40M	$0.69	73.70
Agilent Technologies	$6.95B	5.61	$1.30B	$4.98	27.71

Summary

Agilent Technologies beats Bio-Techne on 12 of the 19 factors compared between the two stocks.

How does Bio-Techne compare to Bio-Rad Laboratories?

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	6.53	$73.40M	$0.69	73.70
Bio-Rad Laboratories	$2.58B	3.15	$759.90M	$6.07	50.16

Bio-Techne presently has a consensus price target of $65.92, suggesting a potential upside of 29.64%. Bio-Rad Laboratories has a consensus price target of $303.33, suggesting a potential downside of 0.37%. Given Bio-Techne's stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bio-Rad Laboratories had 4 more articles in the media than Bio-Techne. MarketBeat recorded 5 mentions for Bio-Rad Laboratories and 1 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.89 beat Bio-Rad Laboratories' score of 0.25 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Techne	Very Positive
Bio-Rad Laboratories	Neutral

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bio-Techne has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Bio-Techne has a net margin of 9.05% compared to Bio-Rad Laboratories' net margin of 6.52%. Bio-Techne's return on equity of 13.57% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

Summary

Bio-Techne beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Bio-Techne compare to Charles River Laboratories International?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Bio-Techne has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	6.53	$73.40M	$0.69	73.70
Charles River Laboratories International	$4.02B	2.16	-$144.34M	-$3.76	N/A

Bio-Techne presently has a consensus price target of $65.92, suggesting a potential upside of 29.64%. Charles River Laboratories International has a consensus price target of $208.50, suggesting a potential upside of 15.77%. Given Bio-Techne's stronger consensus rating and higher probable upside, equities analysts clearly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Charles River Laboratories International had 17 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for Charles River Laboratories International and 1 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.89 beat Charles River Laboratories International's score of 0.79 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Techne	Very Positive
Charles River Laboratories International	Positive

Summary

Bio-Techne beats Charles River Laboratories International on 11 of the 16 factors compared between the two stocks.

How does Bio-Techne compare to Danaher?

Danaher (NYSE:DHR) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.57B	5.14	$3.61B	$5.17	34.51
Bio-Techne	$1.22B	6.53	$73.40M	$0.69	73.70

Danaher has a net margin of 14.89% compared to Bio-Techne's net margin of 9.05%. Bio-Techne's return on equity of 13.57% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	14.89%	10.91%	6.94%
Bio-Techne	9.05%	13.57%	10.66%

Danaher has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

79.1% of Danaher shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 10.8% of Danaher shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.9%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.6%. Danaher pays out 30.9% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has increased its dividend for 2 consecutive years. Danaher is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Danaher presently has a consensus price target of $235.14, suggesting a potential upside of 31.81%. Bio-Techne has a consensus price target of $65.92, suggesting a potential upside of 29.64%. Given Danaher's stronger consensus rating and higher possible upside, analysts plainly believe Danaher is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	4 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, Danaher had 19 more articles in the media than Bio-Techne. MarketBeat recorded 20 mentions for Danaher and 1 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.89 beat Danaher's score of 0.80 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Overall Sentiment
Danaher	Positive
Bio-Techne	Very Positive

Summary

Danaher beats Bio-Techne on 12 of the 20 factors compared between the two stocks.

Get Bio-Techne News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECH vs. The Competition

Export

Metric	Bio-Techne	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.79B	$3.28B	$6.45B	$12.42B
Dividend Yield	0.64%	2.33%	2.69%	5.29%
P/E Ratio	73.70	17.93	22.30	24.19
Price / Sales	6.53	324.62	581.44	138.36
Price / Cash	20.36	116.27	42.31	57.88
Price / Book	4.15	6.63	9.84	6.72
Net Income	$73.40M	$24.20M	$3.57B	$337.19M
7 Day Performance	5.74%	-3.24%	-1.16%	0.48%
1 Month Performance	-7.58%	0.53%	3.85%	5.07%
1 Year Performance	4.24%	47.24%	27.40%	34.25%

Bio-Techne Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECH Bio-Techne	4.1236 of 5 stars	$50.85 +2.2%	$65.92 +29.6%	+2.4%	$7.79B	$1.22B	73.70	3,100	Positive News
BRKR Bruker	1.846 of 5 stars	$45.69 flat	$50.54 +10.6%	+56.0%	$6.96B	$3.44B	N/A	11,085	Analyst Forecast
A Agilent Technologies	4.6917 of 5 stars	$115.01 +0.0%	$163.71 +42.4%	+21.7%	$32.49B	$6.95B	25.39	18,100	Earnings Report Analyst Forecast
BIO Bio-Rad Laboratories	1.023 of 5 stars	$288.55 +0.3%	$303.33 +5.1%	+41.2%	$7.70B	$2.58B	47.54	7,450	News Coverage
CRL Charles River Laboratories International	3.04 of 5 stars	$160.76 +0.3%	$207.69 +29.2%	+29.4%	$7.72B	$4.02B	N/A	19,700	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECH) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Competitors

TECH vs. BRKR, A, BIO, CRL, and DHR

How does Bio-Techne compare to Bruker?

Summary

How does Bio-Techne compare to Agilent Technologies?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Summary

How does Bio-Techne compare to Danaher?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Competitors

TECH vs. BRKR, A, BIO, CRL, and DHR

How does Bio-Techne compare to Bruker?

Is BRKR or TECH more profitable?

Which has more risk & volatility, BRKR or TECH?

Which has preferable valuation and earnings, BRKR or TECH?

Do analysts prefer BRKR or TECH?

Do insiders & institutionals believe in BRKR or TECH?

Does the media refer more to BRKR or TECH?

Is BRKR or TECH a better dividend stock?

Summary

How does Bio-Techne compare to Agilent Technologies?

Which has more volatility and risk, TECH or A?

Is TECH or A more profitable?

Is TECH or A a better dividend stock?

Do analysts prefer TECH or A?

Do institutionals and insiders hold more shares of TECH or A?

Does the media prefer TECH or A?

Which has preferable earnings & valuation, TECH or A?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Which has better earnings & valuation, TECH or BIO?

Do analysts rate TECH or BIO?

Does the media prefer TECH or BIO?

Do institutionals and insiders hold more shares of TECH or BIO?

Which has more risk and volatility, TECH or BIO?

Is TECH or BIO more profitable?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Which has more volatility & risk, TECH or CRL?

Do insiders & institutionals have more ownership in TECH or CRL?

Is TECH or CRL more profitable?

Which has stronger earnings and valuation, TECH or CRL?

Do analysts prefer TECH or CRL?

Does the media prefer TECH or CRL?

Summary

How does Bio-Techne compare to Danaher?

Which has stronger earnings & valuation, DHR or TECH?

Is DHR or TECH more profitable?

Which has more risk and volatility, DHR or TECH?

Do institutionals & insiders have more ownership in DHR or TECH?

Is DHR or TECH a better dividend stock?

Do analysts rate DHR or TECH?

Does the media refer more to DHR or TECH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools